Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

5892 - Pain and quality of life in metastasized Castration Resistant Prostate Cancer patients treated with Radium-223 (ROTOR registry); a prospective observational registry in a non-study population

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Radiation Oncology

Tumour Site

Prostate Cancer

Presenters

Rebecca Louhanepessy

Citation

Annals of Oncology (2018) 29 (suppl_8): viii271-viii302. 10.1093/annonc/mdy284

Authors

R. Louhanepessy1, S. Badrising2, V. Vd Noort3, J..L. Coenen4, A. Oostdijk5, P. Hamberg6, J.M. Zuetenhorst6, A. Beeker7, N. Wagenaar8, M. Lam9, F. Celik10, E. Vegt11, W. Zwart12, A. Bergman12

Author affiliations

  • 1 Medical Oncology, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), 1006 BE - Amsterdam/NL
  • 2 Pulmonary Diseases, Radboud University Medical Center, 6525 HP - Nijmegen/NL
  • 3 Biometrics, Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 CX1 - Amsterdam/NL
  • 4 Medical Oncology, Isala Klinieken, 8025 AB - Zwolle/NL
  • 5 Nuclear Medicine, Isala Klinieken, 8025 AB - Zwolle/NL
  • 6 Medical Oncology, St Franciscus Gasthuis, 3045 PM - Rotterdam/NL
  • 7 Internal Medecine, Spaarne Ziekenhuis, 2134TM - Hoofddorp/NL
  • 8 Nuclear Medicine, Ziekenhuisgroep Twente, 7555 DL - Hengelo/NL
  • 9 Nuclear Medicine, University Medical Center Utrecht, 3584CX - Utrecht/NL
  • 10 Nuclear Medicine, Deventer Ziekenhuis, 7416 - Deventer/NL
  • 11 Nuclear Medicine, Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 CX - Amsterdam/NL
  • 12 Division Of Internal Medicine (mod) And Oncogenomics, Division of Internal Medicine (MOD) and Oncogenomics, 1066CX - Amsterdam/NL
More

Resources

Abstract 5892

Background

In the ALSYMPCA study a survival benefit of Radium-223 (Ra-223) treated metastasized Castration Resistant Prostate Cancer (mCRPC) patients with bone disease was established. However, the effect of Ra-223 treatment on pain and Quality of Life (QoL) was not explored. 200 mCRPC patients treated with Ra-223 in 20 Dutch hospitals were included in the prospective ROTOR registry.

Methods

QoL (FACT-P) and pain (BPI-S) were recorded at Base-Line (BL) and at every Ra-223 cycle. Patients with complete questionnaires at BL and at least one on treatment were included in the analysis. Patients with a BPI-S Pain At Its Worst (PAIW) of ≥ 4 were considered symptomatic. A decrease of FACT-P and BPI-S PAIW of ≥ 6 points and ≥2 points, respectively, were considered clinically meaningfull.

Results

Currently, data is collected from 244 patients. In 101 (41%) patients QoL and pain could be evaluated. Mean age was 72.9 (range 47.8-89.8) years, 85 (83%) had ≥6 bone metastases, an average of 4.8 (CI 4.6-5.1) cycles were administered and 51 (50%) were treated with 6 cycles. The mean total FACT-P in was 70.6 (CI 68.4-72.8). The lowest FACT-P score was at cycle 3 (67.6; CI65.0-70.1) and was 67.0 (CI 66.3-73.6) at cycle 6, which were 3.0 and 3.6 points lower than BL, respectively. The mean total BPI-S score was 43.5 (CI 38.9-48.0) at baseline. Asymptomatic patients (57; 56%) had a PAIW score of 2.1 (CI 1.8-2.5) and a mean total score of 31.0 (CI 25.9-36.0) at base line. The lowest PAIW score was at cycle 5 (1.7; CI 1.1-2.2) and mean total score of 23.4 (CI 16.2-30.6). Symptomatic patients (54; 53%) had a PAIW of 6.9 (CI 6.5-7.2) and a mean total score of 56.0 (CI 51.0-60.9). The lowest PAIW score was at cycle 2 (6.1; CI 5.6-6.6) and mean total score of 53.2 (CI 44.9-59.4) which were 0.8 and 2.8 points lower than base line, respectively. Patients treated with 6 cycles of Ra-223 had a PAIW of 7.1 (CI 6.1-8.2) and a mean score of 56.1 (CI 35.5-67.7).

Conclusions

QoL and pain remained stable during Ra-223 treatment. The lack of pain response might be related to opiate use, which will be analyzed.

Clinical trial identification

NCT03223727.

Legal entity responsible for the study

Netherlands Cancer Institute-Antoni van Leeunwenhoek hospital.

Funding

Bayer.

Editorial Acknowledgement

Disclosure

A. Bergman: Grants: Bayer BV. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.